Clinical Data Ohr Pharmaceuticals announced the Phase 2 data from its study of OHR-102 that "showed that OHR-102 combination therapy enhanced visual acuity in macular edema secondary to retinal vein occlusion".  The data from the study says, "at week 38, the mean gain in visual acuity from baseline for patients randomized at week 10 to continued treatment with OHR-102 + Lucentis PRN was +27.8 letters compared with +23.3 for patients randomized to treatment with Lucentis PRN (control group), a clinically meaningful difference of +4.5 letters".